ABL1 (F317L)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.F317L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Bosutinib | 100.0% | 0.0% | 87.22 |
| 2 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 3 | Dasatinib | 100.0% | 0.0% | 87.97 |
| 4 | Tivozanib | 97.8% | 2.2% | 92.42 |
| 5 | Brigatinib | 97.5% | 2.5% | 82.96 |
| 6 | Nilotinib | 96.1% | 3.9% | 96.49 |
| 7 | Alectinib | 94.3% | 5.7% | 95.49 |
| 8 | Vandetanib | 91.1% | 8.9% | 95.74 |
| 9 | Axitinib | 91.1% | 8.9% | 93.23 |
| 10 | Mobocertinib | 90.9% | 9.1% | 97.22 |
| 11 | Nintedanib | 85.5% | 14.5% | 90.23 |
| 12 | Canertinib | 80.8% | 19.2% | 96.49 |
| 13 | Lenvatinib | 77.0% | 22.9% | 97.74 |
| 14 | Afatinib | 73.7% | 26.3% | 98.50 |
| 15 | Repotrectinib | 71.6% | 28.4% | 84.21 |
| 16 | Pacritinib | 71.4% | 28.6% | 88.64 |
| 17 | Fedratinib | 71.1% | 28.9% | 96.21 |
| 18 | Selpercatinib | 70.9% | 29.1% | 96.72 |
| 19 | Ripretinib | 67.1% | 32.9% | 92.95 |
| 20 | Imatinib | 65.2% | 34.8% | 99.00 |
| 21 | Dacomitinib | 64.4% | 35.6% | 97.99 |
| 22 | Crizotinib | 54.2% | 45.8% | 91.39 |
| 23 | Entrectinib | 48.8% | 51.2% | 93.69 |
| 24 | Ceritinib | 48.7% | 51.3% | 95.44 |
| 25 | Erlotinib | 48.6% | 51.4% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Bosutinib | 100.0% | 99.7% | +0.3% |
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Dasatinib | 100.0% | 98.6% | +1.4% |
| Tivozanib | 97.8% | 95.8% | +2.0% |
| Brigatinib | 97.5% | 82.8% | +14.7% |
| Nilotinib | 96.1% | 98.0% | -1.9% |
| Alectinib | 94.3% | — | — |
| Vandetanib | 91.1% | 95.7% | -4.6% |
| Axitinib | 91.1% | 99.4% | -8.3% |
| Mobocertinib | 90.9% | — | — |
| Nintedanib | 85.5% | 99.9% | -14.3% |
| Canertinib | 80.8% | 91.6% | -10.7% |
| Lenvatinib | 77.0% | 76.3% | +0.7% |
| Afatinib | 73.7% | — | — |
| Repotrectinib | 71.6% | 93.6% | -22.0% |
| Pacritinib | 71.4% | 92.0% | -20.7% |
| Fedratinib | 71.1% | 82.7% | -11.6% |
| Selpercatinib | 70.9% | — | — |
| Ripretinib | 67.1% | 82.9% | -15.7% |
| Imatinib | 65.2% | 86.2% | -20.9% |
| Dacomitinib | 64.4% | 80.8% | -16.4% |
| Crizotinib | 54.2% | 97.0% | -42.8% |
| Entrectinib | 48.8% | — | — |
| Ceritinib | 48.7% | — | — |
| Erlotinib | 48.6% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.0ms